Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This is a phase IV, multicenter, randomized, double blind clinical trial. The investigators
will study 48 patients with remitting relapsing multiple sclerosis (MS) experiencing moderate
or severe attack receiving immunomodulatory therapy or not. Patients will be randomly
assigned to one of the two groups.